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THE LYMPHATICS: NEW TOOLS AND NEW
RESEARCH AVENUES
The lymphatic vasculature maintains tissue homeosta-
sis and sustains immune function by guiding leukocytes and
activated antigen presenting cells toward the lymph nodes.
The lymphatic system is also relevant in cancer progression
because cancer cells frequently spread out of the original
tumor through the lymphatic capillaries.1 The detection of
cancer cells in lymphatic vessels and regional lymph nodes is
a key criterion in the staging of many human tumors, includ-
ing lung cancer, and is used as decisive element for thera-
peutic intervention.2 Although the clinical relevance of lymph
node involvement is well known, the molecular mechanisms
by which tumor cells spread via lymphatic vessels are less
understood. In fact, the study of the lymphatic vasculature has
long been hampered because of a lack of lymphatic-specific
markers. Enormous progress has occurred in this field during
the past decade through the identification of specific lym-
phatic endothelial cell markers such as VEGFR3, the receptor
for vascular endothelial growth factors C and D, the hyaluro-
nan receptor LYVE-1, or the mucin-like transmembrane protein
podoplanin.3 The availability of these markers has allowed the
quantification of lymphatic vessel density in tumor biopsies and
the isolation of lymphatic endothelial cells for in vitro studies.
LYMPHANGIOGENESIS AND CANCER:
MOLECULAR REGULATORY PATHWAYS
Although the hemangiogenic activity of tumor cells
was established decades ago,4 relatively recent data have
shown that tumors are also able to induce lymphangiogenesis
through the production of pro-lymphangiogenic factors such
as VEGF-C.3 What is more relevant, a great number of
clinicopathological studies show good correlation between
lymphatic vessel density in human tumors and poor progno-
sis.1 In fact, consensus criteria for the immunohistochemical
evaluation of lymphangiogenesis in solid tumors have been
recently proposed (Figure 1).5
The information gathered so far about the mechanisms
involved in the regulation of lymphatic vessel growth shows
that there are overlapping molecular players shared between
hemangiogenesis and lymphangiogenesis. The main regula-
tory pathway specific for lymphatic endothelial cells is the
axis formed by VEGFR-3 (also called Flt-4) and its ligands:
VEGF-C and VEGFC-D. VEGFR3 was the first specific
lymphatic endothelial cell marker discovered and shows high
structural homology with VEGFR2, which is more directly
involved in vascular angiogenesis.6 VEGF-C and VEGF-D
are secreted as immature pro-peptides and are proteolyzed by
extracellular convertases.7 Their processing increases their
affinity for VEGFR3 and (less efficiently) for VEGFR2.
Ligand binding induces VEGFR3 tyrosine auto-phosphoryla-
tion and the recruitment of intracellular signaling proteins,
which promote lymphatic endothelial cell proliferation, mi-
gration, and survival.7 Therefore, the expression and activa-
tion of the VEGFC-D/VEGFR3 pathway seem to be a key
molecular link between cancer and lymphangiogenesis, mak-
ing it a good target to prevent the metastatic spread of solid
tumors. Nevertheless, newly published data suggest that the
picture is far more complex. The identification of co-recep-
tors for VEGF-C and VEGF-D such as neuropilin-2,8 or the
1 and 9-integrins, suggests the existence of more intricate
signaling pathways.9 Recent in vivo studies have shown that
the hemangiogenic factor VEGF-A also induces lymphangio-
genesis and promotes tumor metastasis.10 Furthermore, other
growth factors such as angiopoietin, fibroblast growth factor
2, platelet-derived growth factor B, and hepatocyte growth
factor11 stimulate lymphatic vessel growth, suggesting that we
have only spotted the tip of a complicated regulatory process.
Studies performed in animal models strongly suggest
that tumor secreted VEGF-C is also capable of stimulating
the motility and the ability of cancer cells to cross the
lymphatic endothelial wall.12 Nevertheless, there is still some
degree of controversy regarding the relevance of either peri-
tumoral and/or intratumoral lymphatic vessels in solid tu-
mors. On one hand, several findings suggest that the func-
tional lymphatics located in the tumor margin alone are
sufficient for lymphatic metastasis.13 On the other hand,
increasing experimental evidence shows the existence of
intratumoral lymphatics and suggests their association with
poor survival.14 The question of intra- versus peritumoral
localization is interesting when evaluating tumors arising
from organs, such as the lung, with heterogeneous lymphatic
distribution. In the lung, the lymphatic vasculature extends as
far as the bronchioles but fails to reach the alveoli.15
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LYMPHANGIOGENESIS IN LUNG CANCER
Expression studies demonstrated that the levels of
VEGF-C and VEGF-D mRNA and protein are elevated in
small cell lung cancer cell lines.16 Interestingly, the evalua-
tion of VEGF-C, VEGF-D, and VEGFR3 expression in
clinicopathological samples suggest that they are frequently
overexpressed in non-small cell lung cancer (NSCLC) cells.
This increase is associated with lower survival rates.17 More-
FIGURE 1. A, Endothelial growth factors and receptors involved in lymphatic endothelial cell growth signaling. B, Binding of
VEGF-C/D to VEGFR3 leads to its phosphorylation and to the activation of proliferation, migration, and survival pathways. C,
D, Immunohistochemical staining of lymphatic vessels using anti-podoplanin antibody in human lung adenocarcinoma sam-
ples. Left, Tumor marginal lymphatic vessels. Right, Adenocarcinoma cells within the lumen of a lymphatic vessel.
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over, serum VEGF-C determination in NSCLC has been used
as a marker for lymph node metastasis, and its evaluation,
along with computed tomographic examination, has been
proposed as a complement for accurate lymph node staging.18
Despite evidence on the presence of an active proliferating
network of lymphatic vessels in the invading front of lung
adenocarcinomas, a number of questions about lymphangio-
genesis in lung cancer remains: among others, the presence of
intratumoral lymphatics19 or the existence of an association
between its heterogeneous lymphatic support and the fre-
quency of metastatic spread. Finally, it is not clear to what
extent the relevance of lymphatic vasculature in NSCLC
changes with histological type, tumor size, or location within
the lung.
LYMPHANGIOGENESIS INHIBITION
Several approaches have been used for the therapeutic
targeting of tumoral lymphatic growth in preclinical and
clinical studies. Some of them used specific antibodies de-
veloped against VEGF-C, VEGF-D, or VEGFR3 to neutralize
their activity.20 Alternatively, soluble versions of VEGFR3 re-
ceptor have been developed and used in preclinical trials.20 For
example, the overexpression of soluble VEGFR-3 by lung can-
cer cells reduced tumoral lymphatic vessels and the incidence of
metastasis to sentinel lymph nodes in animal models.21 Besides,
some small molecule inhibitors of VEGFR2 kinase activity
that have also been shown to inhibit VEGFR3 kinase
activity are currently being tested in clinical trials. Exam-
ples of these multiple inhibitors are BAY 43-9006 (sor-
afenib), PTK787/ZK222584 (Vatalanib), CEP-7055, and
indolinones such as MAE87 and MAZ51.22
The potential clinical benefit of anti-lymphangiogen-
esis molecular targeted approaches is promising. A combined
therapy to block both hemangiogenesis and lymphangiogen-
esis may even be considered. Nevertheless, some potential
adverse effects, mainly in hematopoiesis and tissue edema,
are strong reasons to act cautiously when translating them
into clinical practice.
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